UroGen Pharma (URGN) Assets Average (2018 - 2026)

UroGen Pharma (URGN) has reported Assets Average for 9 consecutive years, with $227.1 million the latest figure, recorded in Q1 2026.

• Quarterly Assets Average fell 14.85% year-over-year to $227.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $227.1 million (down 14.85% YoY) and the FY2025 annual result came in at $243.1 million, up 4.77% from the prior year.
• Assets Average climbed to $227.1 million in Q1 2026 per URGN's latest filing, from $192.8 million in the prior quarter.
• Over the last five years, Assets Average for URGN reached as high as $293.8 million in Q4 2024 and fell as low as $104.2 million in Q2 2023.
• A 5-year average of $191.5 million and a median of $189.4 million in 2024 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2024 — Assets Average soared 131.58% — and 2025, when it plunged 34.4%.
• Year by year, Assets Average stood at $132.0 million in 2022, then soared by 40.84% to $186.0 million in 2023, then soared by 58.0% to $293.8 million in 2024, then tumbled by 34.4% to $192.8 million in 2025, then climbed by 17.81% to $227.1 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $227.1 million, $192.8 million, and $196.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.